Entheon Issues Incentive Stock Options
Entheon Biomedical Corp (OTCQB: ENTBF) has announced the issuance of stock options to company directors. The granted options allow for the purchase of up to 40,000 common shares at an exercise price of $0.145 per share. These options will remain exercisable for a two-year period from the grant date. The options are governed under the company's incentive stock option plan, which was previously approved by shareholders at the annual general meeting on December 16, 2024.
Entheon Biomedical Corp (OTCQB: ENTBF) ha annunciato l'emissione di opzioni su azioni per i direttori dell'azienda. Le opzioni concesse consentono l'acquisto di fino a 40.000 azioni ordinarie a un prezzo di esercizio di $0,145 per azione. Queste opzioni rimarranno esercitabili per un periodo di due anni dalla data di concessione. Le opzioni sono regolate dal piano di opzioni su azioni incentivanti dell'azienda, precedentemente approvato dagli azionisti nell'assemblea generale annuale del 16 dicembre 2024.
Entheon Biomedical Corp (OTCQB: ENTBF) ha anunciado la emisión de opciones sobre acciones para los directores de la empresa. Las opciones otorgadas permiten la compra de hasta 40,000 acciones comunes a un precio de ejercicio de $0.145 por acción. Estas opciones permanecerán ejercitables por un período de dos años a partir de la fecha de concesión. Las opciones están reguladas bajo el plan de opciones sobre acciones de incentivos de la empresa, que fue aprobado previamente por los accionistas en la reunión general anual del 16 de diciembre de 2024.
Entheon Biomedical Corp (OTCQB: ENTBF)는 회사 이사들에게 주식 옵션을 발행했다고 발표했습니다. 부여된 옵션은 40,000주 보통주를 주당 $0.145의 행사 가격으로 구매할 수 있게 합니다. 이 옵션은 부여일로부터 2년간 행사할 수 있습니다. 옵션은 2024년 12월 16일 연례 총회에서 주주들에 의해 이전에 승인된 회사의 인센티브 주식 옵션 계획에 따라 규제됩니다.
Entheon Biomedical Corp (OTCQB: ENTBF) a annoncé l'émission d'options d'achat d'actions pour les directeurs de l'entreprise. Les options accordées permettent l'achat de jusqu'à 40 000 actions ordinaires à un prix d'exercice de 0,145 $ par action. Ces options resteront exerçables pendant une période de deux ans à partir de la date d'octroi. Les options sont régies par le plan d'options d'achat d'actions incitatives de l'entreprise, qui a été préalablement approuvé par les actionnaires lors de l'assemblée générale annuelle du 16 décembre 2024.
Entheon Biomedical Corp (OTCQB: ENTBF) hat die Ausgabe von Aktienoptionen an die Unternehmensleiter angekündigt. Die gewährten Optionen ermöglichen den Kauf von bis zu 40.000 Stammaktien zu einem Ausübungspreis von $0,145 pro Aktie. Diese Optionen sind für einen Zeitraum von zwei Jahren ab dem Datum der Gewährung ausübbar. Die Optionen unterliegen dem Anreiz-Aktienoptionsplan des Unternehmens, der zuvor von den Aktionären auf der Hauptversammlung am 16. Dezember 2024 genehmigt wurde.
- Stock options align directors' interests with shareholders
- Potential shareholder dilution from 40,000 new stock options
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that the Company has granted options to purchase up to an aggregate 40,000 common shares in the Company (the "Options") to certain directors of the Company. The Options are exercisable at
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.
On Behalf of the Board of Directors,
Timothy Ko, CEO, President and Director
For more information, please contact the Company at:
Entheon Biomedical Corp.
Timothy Ko, CEO
1 (604) 562-3932
timothy@entheonbiomedical.com
https://entheonbiomedical.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246827
FAQ
How many stock options did Entheon Biomedical (ENTBF) grant to directors in March 2025?
What is the exercise price for Entheon Biomedical's (ENTBF) March 2025 stock options?
When do the March 2025 stock options for Entheon Biomedical (ENTBF) expire?
When was Entheon Biomedical's (ENTBF) stock option plan approved by shareholders?
